aids

Pharmaceutical company Grifols to join forces with AIDS research institute IrisCaixa to further investigation into treatments for disease

BCN PrEP·Point follows up with individuals who take the medication “on their own accord” and aims to help research its effects

An international study with the participation of the Hospital Clínic IDIBAPS, which is a leading research centre at a world level on AIDS/HIV and other common diseases, has proved that an anti-retroviral treatment carried out just after the infection delays the damage to the patient’s immune system and reduces the risk of transmission. The results of clinical tests on 366 infected individuals confirmed that the sooner and longer an initial anti-retroviral treatment is applied, the later the life-long treatments have to start. However, despite the results, researchers insist that is still too soon to change the current AIDS/HIV treatment protocols.

The IDIBAPS has opened a new research centre of more than 5,000 m2, where more than 200 researchers split into 23 different research groups will be working. It will focus its work on oncology, neurosciences and cell therapies along with infectious, respiratory, cardiovascular and renal diseases. The new centre has been possible thanks to a donation by the private foundation CELLEX, sponsored by Pere Mir. The new centre is located within the University of Barcelona’s Faculty of Medicine, which is integrated into the prestigious Hospital Clínic. The centre consolidates Catalonia, and in particular Barcelona, as one of Europe’s main biomedical poles.

The scientists working at the HIVACAT project for the development of an effective cure against the HIV virus are hopeful of finding a vaccine in the near future that would stop patients having to be treated for their whole life, actually eradicating the disease. The researchers have tested a first vaccine that has proved effective in reducing the viral load by up to 95%. However, the vaccine effects are only temporary, so researchers will continue the investigation in order to achieve a permanent effect.

This weekend, 14,500 people rocked at the Palau Sant Jordi, in Montjuïc, in a charity concert that brought together the most famous Catalan singers and bands. Singer songwriter Lluís Llach interpreted a poem with former F.C. Barcelona Manager, Pep Guardiola, who finished with the verse: “Everything is to be done, and everything is possible”. 20 more artists participated in the concert, which turned into a cry against AIDS and for the independence of Catalonia.

This world important discovery should open new paths to develop new drugs and to ultimately find a vaccine against HIV/AIDS. The finding has been published in the international journal PLoS Biology. The study has been funded by the Spanish Government, the Catalan Government, La Caixa savings bank, Barcelona’s Hospital Clínic and Esteve Labs.

The vaccine MVA-B against HIV gets a 90% immune response in its first test with humans. In addition, after a year, the vaccine proves to still be effective in 85% of the individuals. The vaccine is still a prototype but it shows a promising perspective. Soon it will be tested as well as a therapeutic vaccine, for people already infected with HIV-AIDS. The vaccine has been developed by the Spanish High Council of Scientific Research (CSIC), in collaboration with Barcelona’s Hospital Clínic and by Madrid’s Hospital Gregorio Marañón.

The NGO and Barcelona's ‘Hospital Clínic’ have helped decrease HIV/AIDS from 90% to 14% in India’s Anantapur District. Both organisations renewed their agreement for another four years. The combined efforts of both organisations have provided health coverage to 90% of HIV infected patients, similar to the rate registered in a developed country.

Two hundred patients are already attended by webcam. The number is expected to grow to 500 over next two years.